z-logo
Premium
Rituximab in refractory and non‐refractory myasthenia: A retrospective multicenter study
Author(s) -
Collongues Nicolas,
Casez Olivier,
Lacour Arnaud,
Tranchant Christine,
Vermersch Patrick,
de Seze Jérôme,
Lebrun Christine
Publication year - 2012
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.23412
Subject(s) - refractory (planetary science) , medicine , rituximab , myasthenia gravis , multicenter study , retrospective cohort study , corticosteroid , anesthesia , gastroenterology , surgery , randomized controlled trial , physics , lymphoma , astrobiology
Few data are available about the effect of rituximab (RTX) on refractory (RM) and non‐refractory (NRM) myasthenia. Methods: This retrospective multicenter study involved 13 RM and 7 NRM patients treated with sequential RTX infusions over 2 years, on average. RTX was used as a substitute for corticosteroids in NRM patients. Disability was assessed using the annualized relapse rate (ARR) and Myasthenia Gravis Foundation of America (MGFA) scores. Results: RTX induction decreased the ARR from 2.1 to 0.3 ( P < 0.001), and lowered MGFA scores from 5–3b to 4b–0 in RM patients, and from 1.9 to 0.1 ( P < 0.001) and 4b–2b to 3b–0 in NRM patients. No side effects were reported in either group, except for 1 case of spondylodiscitis 1 year after the last RTX infusion. Within a year after RTX induction, complete corticosteroid withdrawal was obtained in 7 RM and 4 NRM patients. Conclusions: RTX is efficacious and well‐tolerated. Its use allows for dose reduction or withdrawal of corticosteroids. Muscle Nerve, 2012

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here